| Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis NB Leimkühler, HFE Gleitz, L Ronghui, IAM Snoeren, SNR Fuchs, ... Cell stem cell 28 (4), 637-652. e8, 2021 | 110 | 2021 |
| A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency J Tordo, C O’Leary, ASLM Antunes, N Palomar, P Aldrin-Kirk, M Basche, ... Brain 141 (7), 2014-2031, 2018 | 106 | 2018 |
| Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms HFE Gleitz, AY Liao, JR Cook, SF Rowlston, GMA Forte, Z D'souza, ... EMBO molecular medicine 10 (7), e8730, 2018 | 85 | 2018 |
| Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN HFE Gleitz, AJF Dugourd, NB Leimkühler, IAM Snoeren, SNR Fuchs, ... Blood, The Journal of the American Society of Hematology 136 (18), 2051-2064, 2020 | 79 | 2020 |
| Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy RJ Holley, SM Ellison, D Fil, C O’Leary, J McDermott, N Senthivel, ... Brain 141 (1), 99-116, 2018 | 77 | 2018 |
| Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms HFE Gleitz, A Benabid, RK Schneider Current Opinion in Hematology 28 (5), 364-371, 2021 | 48 | 2021 |
| Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II HFE Gleitz, C O’Leary, RJ Holley, BW Bigger PLoS One 12 (2), e0172435, 2017 | 28 | 2017 |
| Biological drivers of clinical phenotype in myelofibrosis J Mascarenhas, HFE Gleitz, HT Chifotides, CN Harrison, S Verstovsek, ... Leukemia 37 (2), 255-264, 2023 | 26 | 2023 |
| Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis HFE Gleitz, R Kramann, RK Schneider The Journal of pathology 245 (2), 138-146, 2018 | 25 | 2018 |
| An improved adeno-associated virus vector for neurological correction of the mouse model of mucopolysaccharidosis IIIA AL Gray, C O'Leary, A Liao, L Agúndez, AS Youshani, HF Gleitz, H Parker, ... Human Gene Therapy 30 (9), 1052-1066, 2019 | 19 | 2019 |
| Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion USA Stalmann, F Ticconi, IAM Snoeren, R Li, HFE Gleitz, GS Cowley, ... Blood Advances 6 (6), 1780-1796, 2022 | 7 | 2022 |
| Isolation of human bone marrow stromal cells from bone marrow biopsies for single-cell RNA sequencing HFE Gleitz, IAM Snoeren, SNR Fuchs, NB Leimkühler, RK Schneider STAR protocols 2 (2), 100538, 2021 | 6 | 2021 |
| Fibrosis driving myofibroblast precursors in MPN and new therapeutic pathways HFE Gleitz, JE Pritchard, R Kramann, RK Schneider HemaSphere 3, 142-145, 2019 | 2 | 2019 |
| Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II SR Wood, A Chaudrhy, S Ellison, R Searle, C Burgod, G Tehseen, ... Human Gene Therapy 35 (7-8), 232-242, 2024 | 1 | 2024 |
| Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy S Ellison, A Liao, HFE Gleitz, H Parker, L Booth, J Robinson, S Wood, ... Molecular Therapy-Methods & Clinical Development 31, 2023 | 1 | 2023 |
| S205: Inhibiting the alarmin-driven hematopoiesis-stromal cells crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis H Gleitz, I Snoeren, S Fuchs, J Nagai, A Dugourd, C Boys, V Klöker, ... HemaSphere 7, e36177f7, 2023 | 1 | 2023 |
| Transcriptional Landscape of the Microenvironment in Bone Marrow Fibrosis at Single Cell Level NB Leimkühler, R Li, H Gleitz, I Snoeren, S Fuchs, M Crysandt, ... Blood 134, 1675, 2019 | 1 | 2019 |
| Brain targeted stem cell gene therapy provides long-term correction of mucopolysaccharidosis type II B Bigger, AY Liao, H Gleitz, R Holley Molecular Genetics and Metabolism 126 (2), S31-S32, 2019 | 1 | 2019 |
| Whole body correction of severe mucopolysaccharidosis type II by lentiviral-mediated stem cell gene therapy with blood-brain barrier-crossing peptides HFE Gleitz, C O'Leary, RJ Holley, BW Bigger Molecular Genetics and Metabolism 1 (120), S56-S57, 2017 | 1 | 2017 |
| 2003–PHYSICALLY INTERACTING CELL SEQUENCING IN BONE MARROW FIBROSIS REVEALS DISTINCT CELLULAR NICHES IN FIBROSIS H Gleitz, J Nagai, M Ruiz, S Fuchs, I Snoeren, A Boeree, G Cesaro, ... Experimental Hematology 137, 104560, 2024 | | 2024 |
